[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100606429":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":29,"centralContacts":34,"locations":40,"responsibleParty":84,"collaborators":29,"id":86,"slug":87,"hasResults":88,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":29,"eligibilityCriteria":92,"healthyVolunteers":88,"sex":93,"minAge":94,"maxAge":29,"enrollmentInfo":95,"targetDuration":29,"studyType":98,"phases":99,"briefSummary":101,"conditions":102,"keywords":104,"overallStatus":43,"whyStopped":29,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":115},{"fullName":5,"class":6},"Riboscience, LLC.","INDUSTRY",[8,15,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm A: RBS2418, 200mg BID, plus STRIDE","ACTIVE_COMPARATOR","RBS2418 200 mg PO, BID in combination with STRIDE regimen",[13,14],"Drug: RBS2418","Drug: STRIDE (durvalumab + tremelimumab)",{"label":16,"type":10,"description":17,"interventionNames":18},"Arm B: RBS2418, 800mg BID, plus STRIDE","RBS2418 800 mg PO, BID in combination with STRIDE regimen",[13,14],{"label":20,"type":10,"description":21,"interventionNames":22},"Arm C: STRIDE alone (control)","STRIDE regimen",[14],[24,30],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"DRUG","RBS2418","RBS2418 is a specific immune modulator that works through the inhibition of ectonucleotide pyrophosphatase\u002Fphosphodiesterase 1 (ENPP1) and is designed to lead to anti-tumor immunity by protecting endogenous 2'-3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) from hydrolysis and leading to the activation of antigen-presenting cells followed by T cell activation.",[9,16],null,{"type":25,"name":31,"description":32,"armGroupLabels":33,"otherNames":29},"STRIDE (durvalumab + tremelimumab)","STRIDE: Tremelimumab 300 mg IV (Cycle 1 Day 1 only) Plus Durvalumab 1500 mg IV every 4 weeks",[9,16,20],[35],{"name":36,"role":37,"phone":38,"phoneExt":29,"email":39},"Riboscience Clinical Trials","CONTACT","415-754-3182","clinicaltrials@riboscience.com",[41,55,65,75],{"facility":42,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":29},"Johns Hopkins","RECRUITING","Baltimore","Maryland","21218","United States","US",{"type":50,"coordinates":51},"Point",[52,53],-76.61219,39.29038,{"lat":53,"lon":52},{"facility":56,"status":43,"city":57,"state":58,"zip":59,"country":47,"countryCode":48,"cosmosGeoPoint":60,"geoPoint":64,"contacts":29},"Vanderbilt-Ingram Cancer Center","Nashville","Tennessee","37232",{"type":50,"coordinates":61},[62,63],-86.78444,36.16589,{"lat":63,"lon":62},{"facility":66,"status":43,"city":67,"state":68,"zip":69,"country":47,"countryCode":48,"cosmosGeoPoint":70,"geoPoint":74,"contacts":29},"University of Texas Southwestern","Dallas","Texas","75390",{"type":50,"coordinates":71},[72,73],-96.80667,32.78306,{"lat":73,"lon":72},{"facility":76,"status":43,"city":77,"state":68,"zip":78,"country":47,"countryCode":48,"cosmosGeoPoint":79,"geoPoint":83,"contacts":29},"START Dallas Fort Worth","Fort Worth","76104",{"type":50,"coordinates":80},[81,82],-97.32085,32.72541,{"lat":82,"lon":81},{"type":85,"investigatorFullName":29,"investigatorTitle":29,"investigatorAffiliation":29,"oldNameTitle":29,"oldOrganization":29},"SPONSOR","100606429","phase-2-evaluation-of-rbs2418-in-combination-with-tremelimumab-plus-durvalumab-in-participants-with-advanced-unresectable-hepatocellular-carcinoma-100606429",false,"NCT07175441","Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma","A Phase 2a, Multicenter, Randomized, Open-Label Study to Assess the Efficacy, Safety, and Tolerability of RBS2418 in Combination With Tremelimumab Plus Durvalumab for Participants With Advanced Unresectable Hepatocellular Carcinoma","Inclusion Criteria:\n\n1. At least 18 years of age on the day of signing informed consent.\n2. Male and female participants with advanced, unresectable HCC who are eligible to receive STRIDE regimen as first line therapy.\n3. Willing to submit a pre-treatment tissue sample (archival or fresh tissue if archival is not available).\n\nExclusion Criteria:\n\n1. BCLC stage D disease at the time of screening or prior to first dose of RBS2418.\n2. Child-Pugh class equal or higher than B8 at the time of screening or within 7 days prior to the first dose of study treatment.\n3. Eligible for curative treatments (e.g., surgical resection, liver transplantation, or local ablation).\n4. Evidence of rapid progression on prior therapy resulting in rapid clinical deterioration.","ALL","18 Years",{"count":96,"type":97},220,"ESTIMATED","INTERVENTIONAL",[100],"PHASE2","RBS2418 is a targeted immune modulator that inhibits ectonucleotide pyrophosphatase\u002Fphosphodiesterase 1 (ENPP1). It is designed to promote anti-tumor immunity by preserving endogenous 2'-3' cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) from hydrolysis, thereby activating antigen-presenting cells and promoting robust T cell activation. Ideally, RBS2418 acts synergistically with CTLA-4 inhibitors, such as those in the STRIDE regimen (Tremelimumab plus Durvalumab). The hypothesis is that RBS2418 combined with STRIDE will be safe, well-tolerated, highly immunogenic, and enhance anti-tumor responses in adult participants with advanced, unresectable hepatocellular carcinoma (HCC) compared to STRIDE alone.",[103],"Advanced Unresectable Hepatocellular Carcinoma",[105],"Advanced Unresectable Hepatocellular Carcinoma (HCC)","2026-04-22",{"date":108,"type":109},"2026-04-24","ACTUAL",{"date":111,"type":109},"2026-04-10",{"date":113,"type":97},"2027-08",{"name":5,"class":6},4]